Pirfenidone clinical trials
Also written Esbriet and LYT-100.
How each study uses pirfenidone is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the pirfenidone studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- 15 Oct 2014 · ESBRIET · NDA 022535 (FDA, Drugs@FDA)
- European Union
- 28 Feb 2011 · Esbriet · EMEA/H/C/002154 (EMA)
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
101 studies that test it; most in 2017 (10); 1 more planned to start later
| Year | Studies |
|---|---|
| 1999 | 1 |
| 2000 | 1 |
| 2001 | 2 |
| 2002 | 1 |
| 2003 | 2 |
| 2004 | 1 |
| 2005 | 2 |
| 2006 | 3 |
| 2008 | 1 |
| 2009 | 1 |
| 2011 | 2 |
| 2012 | 1 |
| 2013 | 3 |
| 2014 | 1 |
| 2015 | 7 |
| 2016 | 6 |
| 2017 | 10 |
| 2018 | 6 |
| 2019 | 8 |
| 2020 | 8 |
| 2021 | 9 |
| 2022 | 6 |
| 2023 | 5 |
| 2024 | 4 |
| 2025 | 5 |
| 2026 | 5 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 36 · Other 66
Beijing Continent Pharmaceutical Co, Ltd. (6) · Hoffmann-La Roche (6) · Genentech, Inc. (6) · PureTech (5) · University of Guadalajara (4) · Boehringer Ingelheim (3) · National Cancer Institute (NCI) (3) · Qilu Hospital of Shandong University (2)
Often tested with
Tested in the same studies.
Nintedanib (11) · Nerandomilast (2) · Yinfenidone (2) · Methylprednisolone (2) · HRS-9813 (1) · Metformin (1) · Nalbuphine (1) · Silicon (1)
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Tested against it · 2 phase 3 studies under way
Pirfenidone is the comparator. A study of two new drugs counts under both.
- 1AK3280 · Shanghai Ark Biopharmaceutical Co., Ltd. · next primary completion Sep 2028
- 1Yinfenidone · Sunshine Lake Pharma Co., Ltd. · next primary completion Jan 2031
Reaching primary completion within a year · 4, 1 in phase 3
Studies that test pirfenidone, phase 3 first.
- Dec 2026Long Covid (LC)-REVITALIZE - A Long Covid Repurposed Drug StudyPhase 3 · Douglas D. Fraser
- Dec 2026Camrelizumab, Pirfenidone, and Chemotherapy in the Treatment of Advanced Triple-Negative Breast CancerPhase 1/2 · Harbin Medical University
- Jan 2027Targeting Residual Activity By Precision, Biomarker-Guided Combination Therapies of Multiple Sclerosis (TRAP-MS)Phase 1/2 · National Institute of Allergy and Infectious Diseases (NIAID)
- Jan 2027Azithromycin in the Management of Patients With Acute Exacerbation of Idiopathic Pulmonary FibrosisNot applicable · Assiut University
Studies
Open first, then newest update. How each study uses pirfenidone is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 102
- Pirfenidone for Idiopathic Subglottic Stenosis: A Pilot Trial of Tolerability and FeasibilityNot yet recruitingPhase 1London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph'sNCT07654517Written as Pirfenidone
- Trial to Evaluate the Efficacy and Safety of LYT-100 (Deupirfenidone) Compared to Pirfenidone in Adults With Idiopathic Pulmonary Fibrosis (IPF)RecruitingPhase 3PureTechNCT07284602Written as Deupirfenidone
- Targeting Residual Activity By Precision, Biomarker-Guided Combination Therapies of Multiple Sclerosis (TRAP-MS)RecruitingPhase 1/2National Institute of Allergy and Infectious Diseases (NIAID)NCT03109288Written as Pirfenidone
- Long Covid (LC)-REVITALIZE - A Long Covid Repurposed Drug StudyRecruitingPhase 3Douglas D. FraserNCT06928272Written as Pirfenidone
- Paricalcitol Versus Pirfenidone for Improving Surgical Resectability in Patients With Peritoneal CancerNot yet recruitingPhase 2Patrick Wagner, MD, FACSNCT07856914Written as pirfenidone
- Fruquintinib and Pirfenidone in Combination With Anti-PD-1 Antibody in Advanced or Metastatic pMMR/MSS Colorectal CarcinomaRecruitingPhase 2Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyNCT06484153Written as Pirfenidone
- Pirfenidone as Treatment of Chronic PancreatitisNot yet recruitingPhase 2Vikas DudejaNCT07755813Written as Pirfenidone 267 mg Oral Tablet
- Evaluation of Pirfenidone as a Novel Therapeutic Strategy Against Recurrent Acute Pancreatitis.RecruitingPhase 2University of Alabama at BirminghamNCT06253117Written as Pirfenidone
- Azithromycin in the Management of Patients With Acute Exacerbation of Idiopathic Pulmonary FibrosisRecruitingNot applicableAssiut UniversityNCT05842681Written as Pirfenidone
- Pirfenidone to Prevent Fibrosis in Ards.RecruitingPhase 3Università Vita-Salute San RaffaeleNCT05075161Written as Pirfenidone
- Effect of Pirfenidone on TA FibrosisNot yet recruitingPhase 4Shanghai Zhongshan HospitalNCT07325357Written as Pirfenidone Capsules
- Efficacy and Safety of Pirfenidone Capsules in the Treatment of PneumoconiosisRecruitingPhase 3Beijing Continent Pharmaceutical Co, Ltd.NCT05288179Written as Pirfenidone Capsules
- Camrelizumab, Pirfenidone, and Chemotherapy in the Treatment of Advanced Triple-Negative Breast CancerNot yet recruitingPhase 1/2Harbin Medical UniversityNCT07161791Written as Camrelizumab Combined With Pirfenidone and Chemotherapy
- Pirfenidone as a Radiosensitizer in the Treatment of Head and Neck Squamous Cell CarcinomaRecruitingPhase 2Nanfang Hospital, Southern Medical UniversityNCT06142318Written as Pirfenidone
- Pirfenidone Use in Asbestosis Patients: Efficacy and PrognosisNot yet recruitingNot applicableCairo UniversityNCT05133453Written as Pirfenidone
- Prolonged Release Pirfenidone for Advanced Residual Liver Fibrosis (MINERVA).RecruitingPhase 2University of GuadalajaraNCT05542615Written as Prolonged-Release Pirfenidone
- Efficacy and Safety of Pirfenidone in CTD-ILDRecruitingPhase 4Qilu Hospital of Shandong UniversityNCT05505409Written as Pirfenidone
- Safety and Tolerability of Pirfenidone in Acute PancreatitisCompletedPhase 1/2University of Alabama at BirminghamNCT05350371Written as Pirfenidone Oral Tablet
- Study on the Drug Interactions of HRS-9813, Pirfenidone and Nintedanib in Healthy SubjectsCompletedPhase 1Guangdong Hengrui Pharmaceutical Co., LtdNCT07229716Written as Pirfenidone Tablets
- Pifenidone Prophylactic Therapy for Radiation Lung Injury in Patients Who Have Previously Received Immune Checkpoint InhibitorsCompletedPhase 2Hubei Cancer HospitalNCT05801133Written as Pirfenidone
See all 102 studies that test pirfenidone →
Given beside what is tested · 5 — pirfenidone is usual care or a partner of the new treatment
- A Study to Evaluate Pharmacokinetics and Drug-drug Interactions of ENV-101 (Taladegib) in Healthy ParticipantsRecruitingPhase 1Endeavor Biomedicines, Inc.NCT07454291Written as pirfenidone
- Pirfenidone Combined With Standard First-Line Chemotherapy in Advanced-Stage Lung NSCLCCompletedPhase 1H. Lee Moffitt Cancer Center and Research InstituteNCT03177291Written as Pirfenidone
- Efficacy, Safety, and Tolerability Study of Pirfenidone in Combination With Sildenafil in Participants With Advanced Idiopathic Pulmonary Fibrosis (IPF) and Intermediate or High Probability of Group 3 Pulmonary HypertensionCompletedPhase 2Hoffmann-La RocheNCT02951429Written as Pirfenidone
- Safety, Tolerability and PK of Nintedanib in Combination With Pirfenidone in IPFCompletedPhase 4Boehringer IngelheimNCT02579603Written as Pirfenidone
- A Study to Assess the Safety and Tolerability of N-Acetylcysteine When Administered With Pirfenidone to Participants With Idiopathic Pulmonary Fibrosis (IPF)CompletedPhase 2Hoffmann-La RocheNCT02707640Written as Pirfenidone
As the comparator · 7 — what is tested is compared with pirfenidone
- A Phase 3 Study of Efficacy and Safety of AK3280 in Patients With Idiopathic Pulmonary FibrosisNot yet recruitingPhase 3Shanghai Ark Biopharmaceutical Co., Ltd.NCT07719023Written as Pirfenidone
- Confirmatory Clinical Study of HEC585 Tablets in Patients With IPFRecruitingPhase 3Sunshine Lake Pharma Co., Ltd.NCT07082842Written as Pirfenidone
- Phase ll Study of HEC585 in Patients With IPFActive, not recruitingPhase 2Sunshine Lake Pharma Co., Ltd.NCT05060822Written as Pirfenidone
- Comparative Pharmacokinetic(PK) Study of Pirfenidone Modified-Release Tablets and Pirfenidone Tablets in Healthy Subjects Under Fed ConditionsCompletedPhase 1Overseas Pharmaceuticals, Ltd.NCT06588517Written as Pirfenidone Tablets
- Comparative Pharmacokinetic Study of Pirfenidone Modified-Release Tablets and Pirfenidone Tablets in Healthy Subjects Under Fed ConditionsCompletedPhase 1Overseas Pharmaceuticals, Ltd.NCT06589921Written as Pirfenidone Tablets
- Pirfenidone LP or Collagen-polyvinylpyrrolidone in COVID-19CompletedPhase 2/3Materno-Perinatal Hospital of the State of MexicoNCT06585319Written as Pirfenidone 1200 mg
- Randomized, Crossover, Multi-Dose Pharmacokinetics of EXCL-100 Pirfenidone-Sustained Release Tablet and Esbriet in Healthy VolunteersCompletedPhase 1Excalibur Pharmaceuticals, Inc.NCT05428150Written as Esbriet 267 MG Oral Capsule
Codes
What other systems call pirfenidone · ClinicalTrials.gg INT003849
- MeSH (NLM) C093844pirfenidoneConfirmed ClinicalTrials.gov, NLM, Wikidata
- UNII (FDA) D7NLD2JX7UPIRFENIDONEConfirmed FDA, NLM, Wikidata
- RxNorm 1592254Confirmed FDA, Wikidata
- Wikidata Q2060696pirfenidoneConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C2635PirfenidoneOne source FDA
- DrugBank DB04951One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C093844 | pirfenidone | Confirmed ClinicalTrials.gov, NLM, Wikidata |
| UNII (FDA) | D7NLD2JX7U | PIRFENIDONE | Confirmed FDA, NLM, Wikidata |
| RxNorm | 1592254 | — | Confirmed FDA, Wikidata |
| Wikidata | Q2060696 | pirfenidone | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C2635 | Pirfenidone | One source FDA |
| DrugBank | DB04951 | — | One source Wikidata |
Also registered as deupirfenidone (UNII 1QC36BHI6S).
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.